Scott Rocklage and Scientific Research

There is a line of work that few people know about. A venture capitalist is someone who connects to people that want to get things done. It can be in many walks of life and several professions. Scott M. Rockledge Ph.D. of 5 AM Ventures is one of those venture capitalists. Learn more about Michael Lacey: http://www.thestylemaponline.com/the-amazing-career-of-scott-rocklage-of-5am-ventures/

He works in science and works with business opportunities that are in the early stages. Let’s take a look at some other aspects that make him who he is today.

Scott M. Rocklag Ph.D. joined the 5 am Venture company around 2003 and he became their managing partner in 2004. He has over 30 years of experience in healthcare managing and knows how to lead a program towards success. Working with several new drug applications, he has led studies in those drugs. His responsibility was to find and manage people for the study.

He goes between doctors and the labs where the scientific work on the latest creation. Saving lives by finding ways to create new drugs that can help the world to be a healthier place. Not only that, but he makes a lot of money doing so. It’s a winning combination for everyone involved.

He sites his ability to be well organized as his highest level of needed asset to do what he does for a living. He also states that he believes in risk-taking. You cannot be a venture capitalist without that aspect.

Scott values the ability to trust his instincts in order to find the best employee for the job. He has been successfully placing candidates for over thirty years.

He graduated from the University of California with a bachelor of science degree in Chemistry. He later went on to attend and graduate with his Ph.D. from MIT. There, he led research on these drug studies. Located in Boston now, he holds 30 patents and is always pursuing more.

He is published and participated in some of the most prestigious events in the filed of chemistry over the years.

Read more: Sccot Racklage | Bloomberg

Leave a Reply

Your email address will not be published. Required fields are marked *